Additionally, the 36-month beta value for IMUX is 1.48. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMUX is 92.92M and currently, short sellers hold a 2.94% ratio of that float. The average trading volume of IMUX on June 05, 2025 was 1.07M shares.
IMUX) stock’s latest price update
Immunic Inc (NASDAQ: IMUX)’s stock price has soared by 2.80 in relation to previous closing price of 0.77. Nevertheless, the company has seen a gain of 17.14% in its stock price over the last five trading days. proactiveinvestors.com reported 2025-06-05 that Immunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS). The ENSURE program includes two identical, multicenter, randomized, double-blind phase 3 trials, ENSURE-1 and ENSURE-2, designed to assess the efficacy, safety, and tolerability of vidofludimus calcium compared to placebo in patients with RMS.
IMUX’s Market Performance
Immunic Inc (IMUX) has experienced a 17.14% rise in stock performance for the past week, with a -25.54% drop in the past month, and a -30.72% drop in the past quarter. The volatility ratio for the week is 4.26%, and the volatility levels for the past 30 days are at 7.42% for IMUX. The simple moving average for the past 20 days is -10.36% for IMUX’s stock, with a -32.48% simple moving average for the past 200 days.
Analysts’ Opinion of IMUX
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $10. The rating they have provided for IMUX stocks is “Buy” according to the report published on November 25th, 2024.
Leerink Partners gave a rating of “Outperform” to IMUX, setting the target price at $5 in the report published on September 09th of the previous year.
IMUX Trading at -19.24% from the 50-Day Moving Average
After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.24% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMUX starting from Whaley Glenn, who purchase 45,000 shares at the price of $0.71 back on Jun 03 ’25. After this action, Whaley Glenn now owns 95,510 shares of Immunic Inc, valued at $32,076 using the latest closing price.
Rudick Richard Alan, the Director of Immunic Inc, purchase 143,075 shares at $0.70 during a trade that took place back on Jun 03 ’25, which means that Rudick Richard Alan is holding 230,375 shares at $100,024 based on the most recent closing price.
Stock Fundamentals for IMUX
The total capital return value is set at 19.89. Equity return is now at value -246.26, with -154.64 for asset returns.
Based on Immunic Inc (IMUX), the company’s capital structure generated -0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -393.2.
Currently, EBITDA for the company is -100.37 million with net debt to EBITDA at 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
In conclusion, Immunic Inc (IMUX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
